| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer (NCT05168163) | Academic and Community Cancer Research United | 2022-05-27 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant (NCT05103904) | Emory University | 2022-04-19 |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) (NCT05214339) | Sun Yat-sen University | 2022-03-16 |
| DEB-TACE+HAIC vs. HAIC for Large HCC (NCT05263219) | Second Affiliated Hospital of Guangzhou Medical University | 2022-02-10 |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer (NCT05176223) | Mayo Clinic | 2022-01-30 |
| HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure (NCT05135364) | Yue Han | 2021-11-05 |
| Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma (NCT04947956) | Shanghai Zhongshan Hospital | 2021-09-01 |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer (NCT04605731) | City of Hope Medical Center | 2021-08-03 |
| A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (NCT04770896) | Hoffmann-La Roche | 2021-04-26 |
| A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (NCT04829383) | Howard S Hochster | 2021-03-22 |
| Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma (NCT04605185) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-01-08 |
| HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC (NCT05582278) | Wen Li | 2021-01-01 |
| Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001) (NCT07204327) | Zhongda Hospital | 2020-10-28 |
| Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma (NCT04401800) | BeiGene | 2020-09-04 |
| SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT (NCT04387695) | First Affiliated Hospital of Zhejiang University | 2020-04-30 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver (NCT04175912) | National Cancer Institute (NCI) | 2020-03-16 |
| Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) (NCT03896646) | M.D. Anderson Cancer Center | 2019-10-10 |
| Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (NCT03942328) | Mayo Clinic | 2019-09-19 |
| Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study (NCT07305428) | The University of Hong Kong | 2019-04-25 |
| Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer (NCT07298538) | Tianjin Medical University Cancer Institute and Hospital | 2019-01-01 |
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer (NCT03695250) | Edward Kim | 2018-10-16 |
| A Clinical Study of Precision TACE (P-TACE) With Surefire (NCT03345225) | University of Miami | 2018-05-01 |
| Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer (NCT03186898) | NRG Oncology | 2018-01-26 |
| Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells (NCT03107416) | Memorial Sloan Kettering Cancer Center | 2017-04-05 |
| Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma (NCT02989870) | H. Lee Moffitt Cancer Center and Research Institute | 2017-03-27 |
| Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma (NCT02006030) | Polaris Group | 2014-10-15 |
| TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) (NCT02093104) | University of British Columbia | 2014-02-01 |
| Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (NCT01900002) | M.D. Anderson Cancer Center | 2013-09-13 |
| Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (NCT01556490) | Boston Scientific Corporation | 2012-03-01 |
| Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (NCT01217034) | Kindai University | 2010-10-01 |
| Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma (NCT01176604) | M.D. Anderson Cancer Center | 2010-08-04 |
| Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer (NCT01015833) | National Cancer Institute (NCI) | 2010-02-15 |
| Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (NCT01004978) | National Cancer Institute (NCI) | 2009-10-28 |
| Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy (NCT00988741) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2009-09-01 |
| An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer (NCT00247676) | Pfizer | 2006-02-01 |
| Himalaya Early Access Program (NCT05345678) | AstraZeneca | |